Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 3/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731613 | 0.80 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL783654 | 0.80 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL9175738 | 0.80 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL30602927 | 0.76 | GSK3B (0.72) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL2639251 | 0.76 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL6783432 | 0.75 | ADORA3 (0.51) | ADORA3ADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL3306014 | 0.73 | PNP (0.49) | PI4KAPI4K2BPI4K2API4KBCSF1R | |
| SCHEMBL8906323 | 0.71 | AKT2 (0.44) | PI4KAPI4K2BPI4K2API4KBCSF1R | |
| SCHEMBL14022271 | 0.70 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBGSK3B | |
| SCHEMBL28700989 | 0.70 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102335164-B | Application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout | KUNMING PHARMACEUTICAL CORP | 2014-07-30 | — | — | CN | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-102335164-A | Application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout | KUNMING PHARMACEUTICAL CORP | 2012-02-01 | — | — | CN | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | PI4KA 4376/4885PI4K2B 4131/4885PI4K2A 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.